NEW YORK, NY--(Marketwire -01/25/12)- The biotechnology industry has performed well in the early stages of 2012. The iShares NASDAQ Biotechnology Index is presently up nearly eight percent month-on-month as the industry continues to recover nicely from the global economic crisis. According to a recent report from Global Industry Analysts, Inc. (GIA) the improving economic conditions have led to an increase in funding for the biotechnology industry. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Aeterna Zentaris Inc. (NASDAQ: AEZS - News) (TSX: AEZ.TO - News) and Elite Pharmaceuticals Inc. (OTC.BB: ELTP.OB - News). Access to the full company reports can be found at:
GIA predicts the Global Biotechnology Market to Surpass US$320 Billion by 2015, as increased availability of funding for R&D, expanding use of biotechnology in agriculture and medical sciences, and favorable government initiatives are expected to drive growth in the biotechnology industry.
GIA argues that developing markets, especially India and China, will emerge as major agricultural and industrial biotechnology markets owing to rapid increase in population and income levels. "The two countries are emerging as key markets for biotech drugs due to their rich talent pool and low cost of investment," GIA stated in a press release.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Last week the company announced that the initial shipment of methadone hydrochloride 10 mg tablets has been made to ThePharmaNetwork, LLC, and its wholly owned subsidiary, Ascend Laboratories, LLC (together "TPN") under the commercial Manufacturing and Supply Agreement.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer